Chimeric Therapeutics (ASX: CHM) reopens enrolment in CHM CORE-NK plus vactosertib study

May 15, 2024 06:13 PM PDT | By Sonal Goyal

Google News:

Recent News

Klein Funding and Bybit Partner to Launch a New Era of Crypto Prop Tra...

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

Could the Air India Ahmedabad crash derail its turbulent revival?

Uncertainties persist in base metals market regarding US-China trade d...

Highlights

CHM has reopened enrolment in the Phase 1B study of CHM CORE-NK plus vactosertib.

The investigator-sponsored trial is designed to treat 12 patients with locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers.

Chimeric Therapeutics Limited (ASX: CHM) has re-opened the Phase 1B study of CHM CORE-NK plus vactosertib for enrolment. CHM CORE-NK is a universal off-the-shelf NK cell therapy which utilises the CORE-NK platform, capable of producing hundreds of doses within a single manufacturing cycle. The Phase 1B study is an investigator-sponsored study and is currently funded without financial assistance from CHM.

Previous Clinical Trial Findings on CHM CORE-NK

Previously investigated in a Phase 1 clinical trial, CHM CORE-NK demonstrated safety, with no incidence of Graft versus Host Disease (GvHD). The study showed prolonged NK cell persistence up to 28 days, and promising early indications of efficacy, especially in cases of blood cancers. In case of blood cancers, all patients achieved disease control, with one individual maintaining a complete response for over 15 months following the study's publication.

About the Phase 1B trial

Image source: Company update

The trial targets 12 patients diagnosed with either locally advanced/metastatic colorectal cancer, or those experiencing relapsed or refractory blood cancers.

CHM shares traded at AU$0.023 apiece at the time of writing on 16 May 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.